Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

TVM Capital Healthcare Announces the Opening of Baraya Extended Care’s First Outpatient Rehabilitation Clinic in Riyadh




This is the first of nine inpatient and outpatient facilities planned for Baraya across KSA, addressing a gap of 26,000 long-term post-acute care and rehabilitation beds

RIYADH, Saudi Arabia, March 6, 2024 /PRNewswire/ — Baraya Extended Care KSA has launched its first rehabilitation outpatient clinic in Riyadh, Saudi Arabia, offering physical, occupational, speech and language therapy, plus advanced and intensive rehabilitation services. The clinic has the capacity to provide 3,000 rehabilitation sessions per month.

Saudi Arabia faces a significant shortage of long-term post-acute care (LTPAC) and rehabilitation beds. Consequently, this area has been identified as a key priority of Vision 2030 to enhance the healthcare sector. As public hospitals are experiencing capacity constraints, dedicated LTPAC and rehabilitation facilities represent a better way to improve patients’ lives and alleviate the burden on hospitals.

Baraya is a portfolio company of TVM Capital Healthcare’s new fund in KSA, a highly specialised global healthcare investment firm operating in the Middle East since 2009. The firm has an excellent track record and extensive expertise in specialty care and extended care, as the founders of ProVita International Medical Center and Cambridge Medical & Rehabilitation Center.

Looking ahead, Baraya’s second outpatient clinic will open in Jeddah in April 2024. Its first in-patient long-term care hospital is currently under construction and expected to open in Abha by the end of 2025 with a capacity of 216 beds. The long-term care facility will offer specialised services for Saudi’s ageing population suffering from chronic and complex conditions, as well as the younger population who have experienced catastrophic injury or with congenital diseases.

Jad Halaby, Chief Executive of Baraya Extended Care, said: “Our mission is to provide a comprehensive range of services from long-term care and ventilated long-term care to intensive rehabilitation and home healthcare – accessible through a variety of facilities, including clinics and hospitals. We are committed to addressing the critical need for extended care services in the Kingdom. Through our initial nine facilities across three regions (Riyadh, Jeddah, and Abha), we will leverage TVM Capital Healthcare’s expertise to deliver cutting-edge solutions aligned with Vision 2030’s healthcare goals, improving the lives of patients and families in Saudi Arabia by providing exceptional extended care services.

Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, added: “as one of the earliest global healthcare funds operating in the Kingdom since 2015, we have worked hard to bring models that address the greatest needs in KSA private healthcare, and we appreciate the continuous support of the Ministry of Health and the Ministry of Investment in our efforts. Through companies like Provita International Medical Center and Cambridge Medical & Rehabilitation Center, we have been impacting the sector in the UAE and Saudi Arabia for around 14 years, and our new company, Baraya Extended Care is a key step to support the Health Sector Transformation Program. As always, we bring world-class clinical and technical partners to support our activities with their knowledge, standard operating procedures, education and training programmes.”

Othman Abahussein, TVM Capital Healthcare Saudi Operating Partner, concluded: “Baraya emerges as a transformative initiative developed by TVM Capital Healthcare. As a leading provider of rehabilitation and long-term care services, Baraya Extended Care addresses critical gaps within the healthcare sector, ensuring that every individual receives the care they deserve. As investors and residents of the Kingdom, we are excited about the potential of this project to profoundly impact lives, empowering our communities to achieve the quality of life they aspire to.”

About TVM Capital Healthcare:

TVM Capital Healthcare is an emerging markets-focused healthcare private equity firm headquartered in Dubai and Singapore, with offices in Riyadh, Boston, Munich, and Ho Chi Minh City. The firm invests expansion and growth capital in healthcare companies to improve local access to quality care. Investment and operating partners as well as a strong group of Senior Advisors have long-standing international track records in healthcare investing, active board work, contributions to strategy development and implementation, and deep healthcare operations experience. The firm partners with local Middle Eastern and Southeast Asian management teams to build domestic or regional sector champions and selectively backs companies from Europe or North America for expansion into the firm’s target geographies. TVM Capital Healthcare’s investment and operating approach combines strong commercial value creation and returns with impact and responsible (ESG) investing aligned to UN SDGs. 

About Baraya Extended Care:

Baraya Extended Care company was founded and backed by TVM Capital Healthcare, based on its substantial experience in investing and operating healthcare facilities in Saudi Arabia and the UAE, with previous investments such as ProVita and Cambridge Medical & Rehabilitation Center (CMRC). Dedicated to offering comprehensive long-term care, rehabilitation, and at home healthcare services in the Kingdom of Saudi Arabia, Baraya implements new therapeutic tools, latest technologies, and treatment approaches that have significant impact on patient care. Baraya strives to redefine post-acute care standards and elevate patient experiences. The state-of-the-art facilities and a team of skilled professionals will enable the company to deliver innovative and effective solutions across a spectrum of extended care services.

Photo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading